Roche Holding AG (RHHBY) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I'd like to inform you that all participants are in listen-only mode during the call. After the presentation, there will be a question and answer session. You are invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom. In addition to that, you may also raise your virtual hand to address your questions verbally. For participants joining via phone, to raise your hand, use star nine on your phone's dial pad. When you then get selected to ask your questions, please follow the instructions from the phone and press star six to unmute yourself. One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to wish.com slash investors to download the presentation. At this time, it's our pleasure to introduce you to Thomas Schieneker, CEO of Wish Group. Mr. Schieneker, the stage is yours. Thank you very much. And good morning, good afternoon. And I'm happy to share with you our Q3 2025 results. So let's start with our performance. We continue to see strong performance for the Roche Group. Year-to-date group sales still same as half year, it's 7% growth, really driven by pharma with 9%. Diagnostics grew year-to-date with 1%, so we see a return to growth. And diagnostics has of course been impacted by the healthcare pricing reforms in China, something that we have communicated multiple times throughout the year. If we exclude China in the numbers, then the rest of diagnostics was growing 7%, which is absolutely in line with past performance of diagnostics. So we do see that diagnostics continues to perform well. On the LOE impact, we've lowered this now to 800 million impact, down from 1 billion, which we still showed at the half-year results. In Q3, we've had several important miles...